ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0996

Tapering of Corticosteroids or Immunosuppressive Therapy in Stable SLE: A Comparison of Complete Remission, Clinical Remission and Lupus Low Disease Activity State in Protection Against Flares
Abstract Number: 0997

Withdrawal of Maintenance Glucocorticoid versus Other Immunosuppressants Among Patients with Systemic Lupus Erythematosus in Long Term Clinical Remission: Interim Analysis of a Non-inferiority Randomised Controlled Trial
Abstract Number: 0998

A Real-world Analysis Showing Significant Variance in Treatment Patterns Among over 1,000 Systemic Lupus Erythematosus (SLE) Patients in the US
Abstract Number: 0999

Differences in Chromatin Accessibility Pre- and Post-Induction Therapy in Pediatric Lupus
Abstract Number: 1000

Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study
Abstract Number: 1001

Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)
Abstract Number: 1002

Investigation of Pharmacodynamic Biomarkers in a Phase 2b Study in Patients with Moderate to Severe SLE Treated with the S1P1 Receptor Modulator Cenerimod
Abstract Number: 1003

Does LLDAS Definition Match the Rheumatologist Opinion? The First Visit Evaluation of a Longinudital Spanish Multicenter Study to Assess Reasons of Disagreement
Abstract Number: 1004

SPARCC, MASES, LEI and MEI Indexes Capture Different Patients with Enthesitis in Axial Spondyloarthritis, Peripheral Spondyloartrhitis and Psoriatic Arthritis
Abstract Number: 1005

Increasing the Proficiency for Scoring Sacroiliac Joint Radiographs According to the Modified New York Criteria for Ankylosing Spondylitis by Using an Online Real-time Iterative Calibration (RETIC) Module
Abstract Number: 1006

Impact of Uric Acid Levels on Clinical and Radiographic Characteristics in Psoriatic Arthritis and Response to Secukinumab: A Pooled “Post Hoc” Analysis from Five Phase 3 Studies
Abstract Number: 1007

Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study
Abstract Number: 1008

Endothelial Dysfunction in Axial Spondyloarthritis and Its Association with Clinical Disease Characteristics
Abstract Number: 1009

Efficacy and Improvement in Patient-Reported Outcomes at Weeks 16 and 52 in Ixekizumab Treated Biological Naïve Patients with Radiographic Axial Spondyloarthritis Achieving Clinically Important Pain at Night Reduction at Week 16: Results from COAST-V Trial
Abstract Number: 1010

Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].